Assetmark Inc. Increases Holdings in Becton, Dickinson and Company $BDX

Assetmark Inc. increased its stake in Becton, Dickinson and Company (NYSE:BDX) by 49.5% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 225,967 shares of the medical instruments supplier’s stock after acquiring an additional 74,795 shares during the period. Assetmark Inc. owned approximately 0.08% of Becton, Dickinson and Company worth $42,294,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in BDX. Brighton Jones LLC boosted its holdings in shares of Becton, Dickinson and Company by 98.2% in the 4th quarter. Brighton Jones LLC now owns 1,770 shares of the medical instruments supplier’s stock worth $401,000 after purchasing an additional 877 shares during the period. Empowered Funds LLC boosted its position in shares of Becton, Dickinson and Company by 20.4% during the first quarter. Empowered Funds LLC now owns 7,977 shares of the medical instruments supplier’s stock valued at $1,827,000 after buying an additional 1,354 shares during the period. CWM LLC grew its stake in shares of Becton, Dickinson and Company by 87.7% during the second quarter. CWM LLC now owns 22,596 shares of the medical instruments supplier’s stock valued at $3,892,000 after buying an additional 10,560 shares during the last quarter. Sequoia Financial Advisors LLC raised its holdings in shares of Becton, Dickinson and Company by 43.6% in the second quarter. Sequoia Financial Advisors LLC now owns 8,441 shares of the medical instruments supplier’s stock worth $1,454,000 after buying an additional 2,562 shares during the period. Finally, NorthRock Partners LLC purchased a new stake in shares of Becton, Dickinson and Company during the second quarter valued at $325,000. 86.97% of the stock is currently owned by hedge funds and other institutional investors.

Key Stories Impacting Becton, Dickinson and Company

Here are the key news stories impacting Becton, Dickinson and Company this week:

• Positive Sentiment: Citi raised its price target after a life‑sciences sale update, signaling potential value support if BDx proceeds with portfolio moves. Citi raises Becton Dickinson PT to $198
• Positive Sentiment: Jefferies issued a buy, supporting the view that BDx’s portfolio reshaping and product investments can sustain growth. Becton Dickinson Gets a Buy from Jefferies
• Positive Sentiment: TD Cowen nudged its target higher to $189 (hold), reflecting modest upside from current levels and adding another analyst vote of confidence. TD Cowen adjusts Becton Dickinson PT to $189
• Neutral Sentiment: Company Q4 review: management says portfolio reshaping and product investments offset tariff headwinds — useful context for earnings quality but not an immediate directional catalyst. BDX Q4 Deep Dive: Portfolio Reshaping and Product Investments Offset Tariff Headwinds
• Negative Sentiment: Zacks Research cut BDX from “hold” to “strong sell,” a notable downgrade that likely pressured sentiment and contributed to the share weakness. Zacks Research downgrade
• Negative Sentiment: AmericanBankingNews reports Citigroup lowered a prior target (headline shows a cut to $232), adding further mixed signals from the sell‑side. Citigroup Lowers Becton Dickinson PT to $232
• Negative Sentiment: JPMorgan and Wells Fargo issued pessimistic forecasts in separate notes, increasing analyst pressure and downside risk in the near term. JPMorgan pessimistic forecast Wells Fargo pessimistic forecast
• Negative Sentiment: Coverage flow drove a gap‑down headline after the analyst activity, reflecting short‑term selling pressure from downgrades and mixed guidance expectations. Shares gap down on analyst downgrade

Insider Activity at Becton, Dickinson and Company

In related news, EVP Michael David Garrison sold 1,610 shares of Becton, Dickinson and Company stock in a transaction dated Thursday, January 15th. The stock was sold at an average price of $207.46, for a total value of $334,010.60. Following the completion of the transaction, the executive vice president owned 12,095 shares in the company, valued at $2,509,228.70. The trade was a 11.75% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In the last 90 days, insiders sold 2,463 shares of company stock worth $501,530. 0.40% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

A number of equities research analysts have weighed in on BDX shares. TD Cowen lifted their target price on Becton, Dickinson and Company from $183.00 to $189.00 and gave the company a “hold” rating in a research report on Wednesday. Morgan Stanley lifted their price objective on Becton, Dickinson and Company from $197.00 to $210.00 and gave the company an “overweight” rating in a report on Tuesday, December 2nd. Piper Sandler reissued a “neutral” rating and set a $170.00 target price (down previously from $205.00) on shares of Becton, Dickinson and Company in a research report on Tuesday. Royal Bank Of Canada set a $172.00 target price on Becton, Dickinson and Company in a research report on Tuesday. Finally, Zacks Research lowered Becton, Dickinson and Company from a “hold” rating to a “strong sell” rating in a research report on Wednesday. Five analysts have rated the stock with a Buy rating, ten have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $195.46.

Becton, Dickinson and Company Stock Down 1.0%

Becton, Dickinson and Company stock opened at $175.95 on Friday. The business’s 50-day simple moving average is $198.82 and its two-hundred day simple moving average is $192.20. The company has a debt-to-equity ratio of 0.67, a quick ratio of 0.64 and a current ratio of 1.05. The company has a market cap of $50.10 billion, a PE ratio of 28.70, a PEG ratio of 2.32 and a beta of 0.25. Becton, Dickinson and Company has a fifty-two week low of $127.59 and a fifty-two week high of $185.02.

Becton, Dickinson and Company (NYSE:BDX) last released its earnings results on Monday, February 9th. The medical instruments supplier reported $2.91 EPS for the quarter, topping analysts’ consensus estimates of $2.81 by $0.10. Becton, Dickinson and Company had a return on equity of 15.76% and a net margin of 8.01%.The firm had revenue of $5.25 billion during the quarter, compared to the consensus estimate of $5.15 billion. During the same quarter in the previous year, the company posted $3.43 earnings per share. The company’s revenue was up 1.6% compared to the same quarter last year. Becton, Dickinson and Company has set its FY 2026 guidance at 12.350-12.650 EPS. Equities analysts anticipate that Becton, Dickinson and Company will post 14.43 EPS for the current year.

Becton, Dickinson and Company announced that its board has approved a stock buyback program on Tuesday, January 27th that permits the company to buyback $10.00 million in shares. This buyback authorization permits the medical instruments supplier to repurchase up to 0% of its stock through open market purchases. Stock buyback programs are generally an indication that the company’s management believes its shares are undervalued.

Becton, Dickinson and Company Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, March 31st. Investors of record on Tuesday, March 10th will be paid a $1.05 dividend. This represents a $4.20 annualized dividend and a dividend yield of 2.4%. The ex-dividend date is Tuesday, March 10th. Becton, Dickinson and Company’s payout ratio is currently 68.52%.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.